Sowmya Josyula, MD, MPH, and Bobby Daly, MD, MBA, discuss the most commonly recognized administrative barriers faced by physicians using oncology clinical pathways and argue that addressing these burdens is crucial in ensuring provider adoption and seamless patient care.
Recent efforts to develop and validate a patient-reported assessment of the quality of palliative cancer care have been successful.
Clinical pathways may require a deeper consideration of the patient experience in order to achieve the goals of the Triple Aim, according to Winston Wong, PharmD.
Human epidermal growth factor receptor 2 may be a potential marker of poor prognosis in patients with unclassified ovarian cancer, according to a recent meta-analysis.
A plasma-based next-generation sequencing option allows for sensitive detection and monitoring of mutations in advanced non-small cell lung cancer.
A recent study identified patient characteristics that help predict poor 3-year survival in newly diagnosed standard-risk multiple myeloma.
Citing a growing rift between the needs of patients with cancer and the actual care they receive, ESMO highlighted a need for better supportive and palliative care in a recent position paper.
The US Food and Drug Administration has approved a next-generation sequencing assay that may be used as a companion diagnostic for therapy selection for solid tumors.
A recent study found that a significant number of patients with multiple myeloma harbor potentially actionable oncogenic molecular alterations, prompting a need for novel precision medicine approaches.
A recent survey asked patients with primary and recurrent ovarian cancer to consider their reasons for choosing maintenance therapy following surgery and chemotherapy.